| Indicators | Browse All

Vyome Holdings, Inc. (HIND)

Healthcare | Biotechnology | Cambridge, United States | NasdaqCM
2.21 USD -0.01 (-0.226%) ⇩ (Aug. 28, 2026, 4 p.m. EDT)
After hours: 2.15 -0.05 (-0.055%) ⇩ (Aug. 28, 2026, 7:43 p.m. EDT)

Short-term:★★⯪☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | Aug. 22, 2026, 2:24 a.m. EDT

The immediate outlook is flat to slightly negative due to a lack of clear directional momentum, though the recent price action shows some minor stabilization around the $2.20 level. However, the long-term investment case is severely compromised by a catastrophic multi-year decline; the asset has lost virtually all its value over the last eight years, with four consecutive years of negative returns ending recently. This persistent downward trajectory suggests a fundamental deterioration that outweighs any potential recovery thesis. Furthermore, there is no dividend income to offset these risks, as the company has not paid any dividends in the last five years.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.037515
AutoARIMA0.042662
AutoETS0.042663
AutoTheta0.042853

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 44%
H-stat 1.31
Ljung-Box p 0.000
Jarque-Bera p 0.041
Excess Kurtosis 0.92
Attribute Value
Sector Healthcare
Debt to Equity Ratio 0.237
Revenue per Share 0.018
Market Cap 15,475,854
Website https://www.vyometx.com

Info Dump

Attribute Value
52 Week Change -0.7410662
Address1 Harvard Square
Address2 One Mifflin Place Suite 400
All Time High 138,156,000.0
All Time Low 1.75
Ask 2.81
Ask Size 2
Average Daily Volume10 Day 8,610
Average Daily Volume3 Month 14,700
Average Volume 14,700
Average Volume10Days 8,610
Bid 1.6
Bid Size 2
Book Value 0.862
City Cambridge
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 2.205
Current Ratio 4.373
Custom Price Alert Confidence HIGH
Date Short Interest 1,786,665,600
Day High 2.265
Day Low 2.205
Debt To Equity 0.237
Display Name Vyome
Earnings Timestamp End 1,763,064,000
Earnings Timestamp Start 1,763,064,000
Ebitda -4,205,649
Ebitda Margins 0.0
Enterprise To Ebitda -2.109
Enterprise To Revenue 68.367
Enterprise Value 8,868,874
Eps Trailing Twelve Months -1.61
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 2.17466
Fifty Day Average Change 0.030339956
Fifty Day Average Change Percent 0.013951587
Fifty Two Week Change Percent -74.10662
Fifty Two Week High 9.56
Fifty Two Week High Change -7.3550005
Fifty Two Week High Change Percent -0.7693515
Fifty Two Week Low 1.75
Fifty Two Week Low Change 0.45499992
Fifty Two Week Low Change Percent 0.25999996
Fifty Two Week Range 1.75 - 9.56
Financial Currency USD
First Trade Date Milliseconds 1,475,760,600,000
Float Shares 3,645,845
Free Cashflow 3,641,658
Full Exchange Name NasdaqCM
Full Time Employees 9
Fullday Change -0.00500011
Fullday Change Percent -0.22625
Fullday Price 2.15
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.52742
Gross Profits 68,420
Has Pre Post Market Data 1
Held Percent Insiders 0.52881
Held Percent Institutions 0.02178
Implied Shares Outstanding 7,018,528
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,755,216,000
Last Split Factor 1:4
Long Business Summary Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.
Long Name Vyome Holdings, Inc.
Market us_market
Market Cap 15,475,854
Market State CLOSED
Max Age 86,400
Message Board Id finmb_115222623
Most Recent Quarter 1,782,777,600
Net Income To Common -11,307,741
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 15,510,946
Number Of Analyst Opinions 2
Open 2.265
Operating Cashflow -5,578,745
Operating Margins -32.00022
Payout Ratio 0.0
Phone 973 832 8147
Post Market Change -0.05499983
Post Market Change Percent -2.4943233
Post Market Price 2.15
Post Market Time 1,787,960,623
Previous Close 2.21
Price Hint 4
Price To Book 2.5580046
Price To Sales Trailing12 Months 119.29739
Profit Margins 0.0
Quick Ratio 4.312
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.0050001144
Regular Market Change Percent -0.22624952
Regular Market Day High 2.265
Regular Market Day Low 2.205
Regular Market Day Range 2.205 - 2.265
Regular Market Open 2.265
Regular Market Previous Close 2.21
Regular Market Price 2.205
Regular Market Time 1,787,947,200
Regular Market Volume 1,518
Return On Assets -0.48791
Return On Equity -9.99174
Revenue Growth -0.46
Revenue Per Share 0.018
Sand P52 Week Change 0.20504117
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 7,018,528
Shares Percent Shares Out 0.0034999999
Shares Short 24,522
Shares Short Previous Month Date 1,784,073,600
Shares Short Prior Month 38,719
Short Name Vyome Holdings, Inc.
Short Percent Of Float 0.0054
Short Ratio 2.47
Source Interval 15
State MA
Symbol HIND
Target High Price 15.0
Target Low Price 8.0
Target Mean Price 11.5
Target Median Price 11.5
Total Cash 7,887,510
Total Cash Per Share 1.124
Total Debt 17,310
Total Revenue 129,725
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -1.61
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 2.77625
Two Hundred Day Average Change -0.57124996
Two Hundred Day Average Change Percent -0.20576316
Type Disp Equity
Volume 1,518
Website https://www.vyometx.com
Zip 2,138